| P2093 | author name string | Jaime Uribarri | |
| | Susan Whiting | |
| | Sarah Sanghavi | |
| P2860 | cites work | A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group | Q28307394 |
| | Low-potassium and glucose-free dialysis maintains urea but enhances potassium removal | Q32035319 |
| | Enhanced large intestinal potassium permeability in end-stage renal disease | Q34403879 |
| | Hyperkalemia in dialysis patients | Q34419220 |
| | Effects of oral potassium on blood pressure. Meta-analysis of randomized controlled clinical trials | Q34427431 |
| | A randomized controlled trial of fludrocortisone for the treatment of hyperkalemia in hemodialysis patients. | Q34516576 |
| | Renin-angiotensin system blockade and the risk of hyperkalemia in chronic hemodialysis patients. | Q34522529 |
| | Regulation of active sodium and potassium transport in the distal colon of the rat. Role of the aldosterone and glucocorticoid receptors | Q34581362 |
| | In-Center Hemodialysis Six Times per Week versus Three Times per Week | Q34588347 |
| | Sodium and potassium in the pathogenesis of hypertension | Q34627313 |
| | Angiotensin converting enzyme inhibitors or angiotensin receptor blockers in nephropathy from type 2 diabetes | Q34633316 |
| | Depressive symptoms and dietary adherence in patients with end-stage renal disease | Q34683825 |
| | Nonadherence in hemodialysis: associations with mortality, hospitalization, and practice patterns in the DOPPS. | Q35145471 |
| | The effect of diet education on the laboratory values and knowledge of hemodialysis patients with hyperphosphatemia | Q35636802 |
| | Drug therapy for hypertension in hemodialysis patients | Q35834740 |
| | Dialysis outcomes and analysis of practice patterns suggests the dialysis schedule affects day-of-week mortality | Q36002351 |
| | Serum potassium and cause-specific mortality in a large peritoneal dialysis cohort | Q36126907 |
| | Phosphorus and potassium content of enhanced meat and poultry products: implications for patients who receive dialysis | Q37297606 |
| | Left ventricular mass in chronic kidney disease and ESRD. | Q37649218 |
| | Hyponatremia and hypokalemia in patients on peritoneal dialysis | Q37814442 |
| | Angiotensin receptor blockers reduce left ventricular hypertrophy in dialysis patients: a meta-analysis | Q38047213 |
| | Long interdialytic interval and mortality among patients receiving hemodialysis | Q38436593 |
| | Serum and dialysate potassium concentrations and survival in hemodialysis patients | Q38461253 |
| | Losartan antagonism of angiotensin-II-induced potassium secretion across rat colon | Q38462284 |
| | Effects of telmisartan added to Angiotensin-converting enzyme inhibitors on mortality and morbidity in hemodialysis patients with chronic heart failure a double-blind, placebo-controlled trial | Q42821650 |
| | Emerging importance of residual renal function in end-stage renal failure | Q44232525 |
| | Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms | Q44272913 |
| | Control of serum potassium during fasting in patients with end-stage renal disease | Q44574748 |
| | Effects of an ACE inhibitor or angiotensin receptor blocker on potassium in CAPD patients | Q45071580 |
| | Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events | Q45152747 |
| | Electrolyte abnormalities and laboratory findings in patients with out-of-hospital cardiac arrest who have kidney disease. | Q45326045 |
| | Effects of sodium intake and diet on racial differences in urinary potassium excretion: results from the Dietary Approaches to Stop Hypertension (DASH)-Sodium trial | Q46589841 |
| | Effect of various therapeutic approaches on plasma potassium and major regulating factors in terminal renal failure | Q46900375 |
| | Prevention of sudden cardiac death: rationale and design of the Implantable Cardioverter Defibrillators in Dialysis patients (ICD2) Trial--a prospective pilot study | Q47629144 |
| | Prolonged therapy with ACE inhibitors induces a regression of left ventricular hypertrophy of dialyzed uremic patients independently from hypotensive effects. | Q50626216 |
| | The effects of angiotensin converting enzyme inhibitors on potassium homeostasis in dialysis patients with and without residual renal function. | Q52849241 |
| | Mineralocorticoid therapy lowers serum potassium in patients with end-stage renal disease. | Q53872162 |
| P433 | issue | 5 | |
| P921 | main subject | renal dialysis | Q202301 |
| P304 | page(s) | 597-603 | |
| P577 | publication date | 2013-09-01 | |
| P1433 | published in | Seminars in Dialysis | Q15761546 |
| P1476 | title | Potassium balance in dialysis patients | |
| P478 | volume | 26 | |